Loading company
Arrowhead Pharmaceuticals, Inc.
ARWR · Nasdaq · ·
$66.21+1.1%Sep 29 close
- 1M
- -22.0%
- 6M
- +14.8%
- 1Y
- +92.0%
- 5Y
- +1.0%
ARWR · Nasdaq · ·
$66.21+1.1%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $75.3M | $27.8M | +171.02% |
| Profit | -$194.3M | -$175.2M | -10.86% |
| Profit per share | -$1.36 | -$1.26 | -7.94% |
| Free Cash Flow | -$181.3M | -$157.1M | -15.43% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Arrowhead Pharmaceuticals, Inc. has no earnings call transcript available.
“The recent period for Arrowhead included transformational events that support continued growth,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Arrowhead Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.